Evidence map›Paper›PMID 33320168›Full record

Trial reportInvestigative ophthalmology & visual science2020

Effects of Atropine Treatment on Choroidal Thickness in Myopic Children.

Luyao Ye, Ya Shi, Yao Yin, Shanshan Li, Jiangnan He, Jianfeng Zhu, Xun Xu

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigative ophthalmology & visual science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06265454 (Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children), which is not on this map. Cited by 38 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06265454 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Effect of Low Concentration Atropine Eye Drops on Choroidal Thickness, Central Corneal Thickness, Anterior Scleral Thickness and Axial Length in Myopic Children

TypeinterventionalSponsorAin Shams UniversityRan2024 to 2026Enrolled75ConditionsMyopia Progression, Axial Length, Eye, Sclera ThicknessArmslow dose atropine eye drops, Placebo
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Effect of 0.01% Atropine on Choroidal Thickness and Ocular Growth in Pre-myopic Children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Article
  18. IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Luyao YeShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Ya ShiShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Yao YinShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Shanshan LiShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Jiangnan HeShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Jianfeng ZhuShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Xun XuShanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China.
Shanghai Eye Disease Prevention & Treatment Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To examine the changes in choroidal thickness (ChT) after 6 months of 1% or 0.01% atropine treatment and the independent factors associated with eye elongation. Methods: A total of 207 myopic children aged 6 to 12 years were recruited and randomly assigned to groups A and B in a ratio of 1:1. Participants in group A received 1% atropine once a day for 1 week, and then once a week for 23 weeks. Participants in group B received 0.01% atropine once a day for 6 months. ChT and internal axial length (IAL) were measured at baseline, 1 week, 3 months, and 6 months. Results: In group A, the ChT significantly increased after a 1-week loading dose of 1% atropine (26 ± 14 µm; P < 0.001) and the magnitude of increase stabilized throughout the following weekly treatment. The internal axial length did not significantly change at the 6-month visit (-0.01 ± 0.11 mm; P = 0.74). In contrast, a decreased ChT (-5 ± 17 µm; P < 0.001) and pronounced eye elongation (0.19 ± 0.12 mm; P < 0.001) were observed in group B after 6 months. Multivariable regression analysis showed that less increase in ChT at the 1-week visit (P = 0.03), younger age (P < 0.001), and presence of peripapillary atrophy (P = 0.001) were significantly associated with greater internal axial length increase over 6 months in group A. Conclusions: One percent atropine could increase the ChT, whereas 0.01% atropine caused a decrease in ChT after 6 months of treatment. For participants receiving 1% atropine, the short-term increase in ChT was negatively associated with long-term eye elongation. Younger age and the presence of peripapillary atrophy were found to be risk factors for greater eye elongation.

Indexed as

AtropineChildChoroidFundus OculiHumansMyopiaOphthalmic SolutionsTomography, Optical CoherenceAtropineOphthalmic Solutions

Identifiers

PMID33320168
PMCPMC7745623
OpenAlexW3112869609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.